Tirzepatide vs GLP-1 Receptor Agonists: Mechanism and Class Compared

One of the most common framings in incretin pharmacology is whether tirzepatide belongs inside the GLP-1 receptor agonist class or sits alongside it. The published literature answers this at the level of receptor targets: tirzepatide engages the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, whereas the selective GLP-1 receptor agonists act at the GLP-1 receptor alone. A 2022 review in Cardiovascular Diabetology described tirzepatide as a dual GIP/GLP-1 receptor co-agonist developed for type 2 diabetes (PMID 36050763). This page summarises that pharmacology as reported, and does not frame any compound as a choice.

This page is for educational purposes only and is not medical advice; consult a licensed physician or prescribing clinician about any medicine, including whether an incretin-based therapy is appropriate in an individual situation.

Is Tirzepatide a GLP-1 Receptor Agonist?

In the strict pharmacological sense, tirzepatide does act as an agonist at the GLP-1 receptor — but that is only half of its described activity. Reviews characterise it as a dual incretin receptor agonist, meaning a single molecule with measurable agonist activity at two distinct class B G-protein-coupled receptors. The Cardiovascular Diabetology review used the term "dual GIP/GLP-1 receptor co-agonist" to distinguish it from mono-agonists of the GLP-1 receptor (PMID 36050763). A systematic update in the International Journal of Molecular Sciences likewise framed tirzepatide as acting through both incretin receptors (PMID 36498958).

So the accurate description reported in the literature is: tirzepatide includes GLP-1 receptor agonism within its mechanism, and adds GIP receptor agonism that the selective GLP-1 receptor agonists do not have. Many reviews therefore group it under a broader "GLP-1-based medications" or "incretin-based therapies" umbrella while noting the additional receptor. A 2025 mechanistic review in Medicina Clínica grouped GLP-1-based medications together when describing mechanisms involved in obesity treatment (PMID 40466247).

Not Equal Activity at Both Receptors

An important nuance comes from receptor-level pharmacology rather than clinical trials. A 2020 study in JCI Insight characterised tirzepatide as an imbalanced and biased dual GIP and GLP-1 receptor agonist, meaning its potency at the two receptors differed and its signalling downstream of the GLP-1 receptor was biased toward particular pathways rather than reproducing native GLP-1 signalling proportionally (PMID 32730231). That study is the usual reference point for why tirzepatide is not simply "a GLP-1 agonist with GIP added on top" — the GLP-1 arm itself behaves differently from a conventional selective agonist in laboratory signalling assays (PMID 32730231).

Receptor Targets Side by Side

How the GLP-1 Arm Is Described

The GLP-1 receptor component of tirzepatide's activity shares mechanistic territory with the selective agonists. A 2025 review in The American Journal of Medicine examined mechanisms of GLP-1 receptor agonist-induced weight loss and described both central pathways — hypothalamic and brainstem circuits involved in appetite and satiety — and peripheral pathways involved in energy regulation (PMID 39892489). The Medicina Clínica review covering GLP-1-based medications similarly set out mechanisms relevant to obesity treatment across the class (PMID 40466247).

Glucose-dependent insulin secretion is the other shared feature. Because incretin receptor agonism amplifies insulin release in a glucose-dependent fashion, reviews of the class have emphasised that the insulinotropic effect is tied to prevailing glucose levels rather than being unconditional (PMID 36050763).

What the GIP Arm Adds in Preclinical Work

The contribution of GIP receptor agonism is an active research question. A 2024 study in Diabetes, Obesity & Metabolism administered tirzepatide to obese type 2 diabetic db/db mice and reported favourable effects on pancreatic β-cells and on hepatic steatosis in that model (PMID 39344853). Findings in rodent models do not transfer automatically to human physiology, and that study was explicitly an animal investigation (PMID 39344853).

Structure and Peptide Design

Tirzepatide is a synthetic peptide engineered from the GIP sequence backbone with modifications that give it activity at both incretin receptors and a half-life compatible with once-weekly administration. The systematic update in IJMS reviewed tirzepatide's development and pharmacology as a single-molecule dual agonist (PMID 36498958). Selective GLP-1 receptor agonists, by contrast, derive from the GLP-1 sequence or from exendin-4, with modifications that resist degradation by dipeptidyl peptidase-4.

The practical consequence described in receptor-pharmacology work is that a GIP-based backbone with engineered GLP-1 receptor activity does not necessarily reproduce the signalling profile of a GLP-1-derived peptide — which is precisely the "biased agonism" point reported in the JCI Insight characterisation (PMID 32730231).

Body Composition and Comparative Evidence

Network meta-analysis has been used to compare agents within and adjacent to the class. A 2025 systematic review and network meta-analysis in Metabolism examined the effect of GLP-1 receptor agonists and co-agonists on body composition, pooling trials across the agents and reporting on changes in fat mass and lean mass compartments (PMID 39719170). That analysis treated co-agonists such as tirzepatide as a distinct node from mono-agonists, which is itself informative about how the field classifies them (PMID 39719170).

A 2025 review in Expert Opinion on Pharmacotherapy covered tirzepatide for overweight and obesity management, summarising the trial programme supporting its evaluation in that indication (PMID 39632534). The 2022 Cardiovascular Diabetology review characterised the glycaemic control and body-weight reduction observed with tirzepatide in its type 2 diabetes trial programme as unmatched relative to comparators available at the time (PMID 36050763). Questions about what any of this means for an individual belong with a prescribing clinician.

Regulatory Status

Tirzepatide is a prescription medicine. A 2023 drug monograph in The Senior Care Pharmacist introduced it under the brand name Mounjaro as a new agent for type 2 diabetes (PMID 36751934). The selective GLP-1 receptor agonists are likewise prescription medicines evaluated through regulated clinical trial programmes and reviewed collectively in the GLP-1-based medications literature (PMID 40466247). Which product carries which approved indication, and in which territory, is determined by the relevant regulator and by the prescribing information, and is a matter for a licensed clinician and pharmacist.

Tolerability: What Studies Report

Gastrointestinal effects dominate the reported tolerability profile across incretin-based agents. A 2024 review in The Lancet Gastroenterology & Hepatology examined the gastrointestinal effects of GLP-1 receptor agonists, covering the mechanisms behind nausea, vomiting, diarrhoea and constipation, their management, and future research directions (PMID 39096914). Delayed gastric emptying is one of the mechanisms discussed in that review as contributing to both the therapeutic and the adverse gastrointestinal profile (PMID 39096914).

Interaction considerations have also been described specifically because of gastric emptying. A 2024 analysis in the Journal of the American Pharmacists Association examined the impact of tirzepatide and GLP-1 receptor agonists on oral hormonal contraception, a question that arises from altered gastrointestinal transit and absorption (PMID 37940101).

Dermatological observations have been reviewed separately. A comprehensive review in Anais Brasileiros de Dermatologia covered cutaneous adverse events associated with tirzepatide alongside emerging therapeutic roles and cosmetic implications of rapid weight change (PMID 41483501). Body-composition shifts, including changes in lean mass, were the focus of the Metabolism network meta-analysis of GLP-1 receptor agonists and co-agonists (PMID 39719170). Any assessment of these reports in an individual context is a clinical matter.

How to Read Comparisons of This Kind

• Receptor count is not a ranking. Two receptor targets describe a different mechanism, not an automatically superior one; the JCI Insight work showed the signalling is imbalanced and biased rather than additive (PMID 32730231).
• Class reviews often pool agents. The Medicina Clínica mechanism review treated GLP-1-based medications as one mechanistic family (PMID 40466247), so "GLP-1 drug" in a paper's title may or may not include co-agonists.
• Indication matters. Tirzepatide was introduced for type 2 diabetes (PMID 36751934) and separately reviewed for overweight and obesity management (PMID 39632534); evidence sets differ by indication.
• Species matters. β-cell and hepatic steatosis findings were reported in db/db mice (PMID 39344853).

For a deeper overview of the compound itself, see the PeptideU learn page on tirzepatide. Nothing on this page constitutes a recommendation, and all questions about suitability, safety, monitoring or alternatives are for a prescribing clinician.

References

• Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction (Cardiovascular Diabetology, 2022)
• Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (JCI Insight, 2020)
• Tirzepatide: A Systematic Update (International Journal of Molecular Sciences, 2022)
• GLP-1-based medications: Mechanisms involved in obesity treatment (Medicina Clinica, 2025)
• Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation (The American Journal of Medicine, 2025)
• Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis (Metabolism, 2025)
• Tirzepatide for overweight and obesity management (Expert Opinion on Pharmacotherapy, 2025)
• New Drug: Tirzepatide (Mounjaro) (The Senior Care Pharmacist, 2023)
• Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions (The Lancet Gastroenterology & Hepatology, 2024)
• The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception (Journal of the American Pharmacists Association, 2024)
• Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications - A comprehensive review (Anais Brasileiros de Dermatologia, 2026)
• Tirzepatide, a dual GIP/GLP-1 receptor agonist, exhibits favourable effects on pancreatic β-cells and hepatic steatosis in obese type 2 diabetic db/db mice (Diabetes, Obesity & Metabolism, 2024)